The combination drugs debate: Incompatibility problems can be overcome - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The combination drugs debate: Incompatibility problems can be overcome


Pharmaceutical Technology Europe
Volume 21, Issue 9

For an alternative view on combination drugs, go to http://www.pharmtech.com/unstable


(David Gould/Getty Images)
With declining numbers of new chemical entities (NCEs), there is a new-found aggression for developing differentiated products using currently approved drugs. Fixed drug combination products have emerged as a differentiation strategy, as is evident by the increasing number of such product approvals1 and recent launches. The strategy involves identifying molecules that, when combined, will lead to an improved therapeutic outcome compared with other treatment options. The rationale for such products are the associated advantages, such as improved patient compliance, complementary pharmacodynamic effect and improved bioavailability. Product stability, however, is a common and significant factor affecting the outcome of the product development project.

What are the stability issues?

Stability problems in combination products can be attributed to three types of interaction:
  • Drug–drug chemical interaction: two or more drugs interact directly, resulting in drug degradation and a number of impurities; for example, lisinopril combined with aspirin undergoes acetylation to generate acetyl lisinopril,2 which could lead to a number of possible adverse events.
  • Drug–excipient interaction: a drug in a combination product has an excipient that is incompatible with other drugs; for example, telmisartan in a telmisartan-hydrochlorothiazide combination product needs the incorporation of an alkaline excipient. Hydrochlorothiazide, however, degrades in an alkaline environment.3
  • Drug–excipient–drug interaction: occasionally, combination drugs, which may not be interacting directly, exhibit incompatibility in the presence of certain formulation components; for example, the combination of rifampicin and isoniazide is stable unless there is any excipient or agent that creates an acidic or alkaline environment.4

The incompatibility interactions are often facilitated by the close contact between drugs and excipients. There are other factors such as the pH of the formulation microenvironment, temperature and moisture — all of which initiate and catalyse chemical reactions.

The instability of combination drugs is manifested in various forms that can be broadly classified into three groups: physical instability, which includes changes in physical appearance (e.g., colour, precipitation, hardness, etc.); chemical instability — variation in drug content and impurities; and functional instability — changes in the drug release pattern.

We can address incompatibility challenges

Significant research has been conducted to understand the root cause of drug incompatibility issues. The vast amount of literature and knowledge on the structural and chemical properties of drugs and excipients can help development teams to assess possible incompatibilities and make a development strategy that addresses such challenges effectively.

As previously mentioned, the instability of combination products is mainly the result of incompatibility between formulation components; for example, drug and excipients. A systematic development strategy is the first step to detect any potential compatibility issues and accordingly design the product. It is, therefore, possible, to safely develop a combination drug product that is stable and has a sufficient shelf-life, so long as the following key factors are considered: preformulation and degradation; dosage form selection; packaging development; preclinical studies; and product specification.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here